5,477
edits
Metformin weight loss: Difference between revisions
no edit summary
(Created page with "{{Short description|Metformin, insulin resistance, weight loss, and type 2 diabetes prevention}} thumb|right|300px|Chemical structure of [[metformin, a biguanide medication commonly used for type 2 diabetes, prediabetes, insulin resistance, and selected cases of polycystic ovary syndrome.]] thumb|right|350px|[[Meal replacement shakes may help selected patients with insulin resistance, predi...") |
No edit summary |
||
| Line 3: | Line 3: | ||
[[File:Weight-loss-shakes.jpeg|thumb|right|350px|[[Meal replacement]] shakes may help selected patients with [[insulin resistance]], [[prediabetes]], [[type 2 diabetes]], and [[obesity]] achieve structured [[calorie restriction]] and [[weight loss]].]] | [[File:Weight-loss-shakes.jpeg|thumb|right|350px|[[Meal replacement]] shakes may help selected patients with [[insulin resistance]], [[prediabetes]], [[type 2 diabetes]], and [[obesity]] achieve structured [[calorie restriction]] and [[weight loss]].]] | ||
[[File:W8md-meal-replacementnts.png|thumb|right|350px|[[W8MD Weight Loss, Sleep and MedSpa]] Centers offer physician-supervised [[medical weight loss]], [[meal replacements]], [[low-carbohydrate diet]] counseling, [[GLP-1 weight loss]] options, and [[sleep apnea]] care.]] | [[File:W8md-meal-replacementnts.png|thumb|right|350px|[[W8MD Weight Loss, Sleep and MedSpa]] Centers offer physician-supervised [[medical weight loss]], [[meal replacements]], [[low-carbohydrate diet]] counseling, [[GLP-1 weight loss]] options, and [[sleep apnea]] care.]] | ||
'''Metformin, insulin resistance, and weight loss''' refers to the role of [[metformin]], [[medical weight loss]], [[nutrition therapy]], [[physical activity]], [[sleep apnea]] treatment, and newer [[GLP-1 receptor agonist]] medications in improving or slowing [[insulin resistance]], a central driver of [[prediabetes]], [[metabolic syndrome]], [[polycystic ovary syndrome]], [[fatty liver disease]], and [[type 2 diabetes]]. [[Insulin resistance]] occurs when [[muscle]], [[fat]], and [[liver]] cells do not respond normally to [[insulin]], causing the [[pancreas]] to make more insulin to keep [[blood glucose]] in range. Over time, the pancreas may not keep up, leading to [[prediabetes]] and eventually [[type 2 diabetes]].{{cite web|url=https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/prediabetes-insulin-resistance|title=Insulin Resistance and Prediabetes|publisher=National Institute of Diabetes and Digestive and Kidney Diseases|accessdate=June 24, 2026}}{{cite web|url=https://www.cdc.gov/diabetes/about/insulin-resistance-type-2-diabetes.html|title=About Insulin Resistance and Type 2 Diabetes|publisher=Centers for Disease Control and Prevention|accessdate=June 24, 2026}} | '''Metformin, insulin resistance, and weight loss''' refers to the role of [[metformin]], [[medical weight loss]], [[nutrition therapy]], [[physical activity]], [[sleep apnea]] treatment, and newer [[GLP-1 receptor agonist]] medications in improving or slowing [[insulin resistance]], a central driver of [[prediabetes]], [[metabolic syndrome]], [[polycystic ovary syndrome]], [[fatty liver disease]], and [[type 2 diabetes]]. [[Insulin resistance]] occurs when [[muscle]], [[fat]], and [[liver]] cells do not respond normally to [[insulin]], causing the [[pancreas]] to make more insulin to keep [[blood glucose]] in range. Over time, the pancreas may not keep up, leading to [[prediabetes]] and eventually [[type 2 diabetes]].{{cite web|url=https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/prediabetes-insulin-resistance|title=Insulin Resistance and Prediabetes|publisher=National Institute of Diabetes and Digestive and Kidney Diseases|accessdate=June 24, 2026}}{{cite web|url=https://www.cdc.gov/diabetes/about/insulin-resistance-type-2-diabetes.html|title=About Insulin Resistance and Type 2 Diabetes|publisher=Centers for Disease Control and Prevention|accessdate=June 24, 2026}} | ||